BioSpace News Archive

Policy

Government of Canada Announces Funding to Help End Gender-Based Violence in LGBTQ2 Communities

Projects will help break down barriers to gender equality and support in LGBTQ2 communities

May 17, 2019
·
3 min read
Business

NIH administers first clinical trial treatment for GM1 created by Auburn, UMass

Milestone marks the first patient with GM1 gangliosidosis treated with gene therapy

May 17, 2019
·
5 min read
Business

AAC Webcast Replay Available Until May 27, 2019

AAC Holdings, Inc. hosted a conference call in which company leadership discussed near term plans to improve its operational results and balance sheet, including through potential transactions involving the company’s owned real estate.

May 17, 2019
·
4 min read
Policy

AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).

May 17, 2019
·
2 min read
FDA

FDA Approves First VTE Treatment for Pediatric Patients

Pfizer’s Fragmin was approved to reduce the recurrence of VTE in patients one month of age or older.

May 17, 2019
·
2 min read
·
Alex Keown
Drug Development

Puma’s Nerlynx Edges Out Novartis’ Tykerb in Breast Cancer Trial

Patients were randomized 1:1 to receive Nerlynx and Xeloda or Tykerb and Xeloda. Co-primary endpoints were progression-free survival and overall survival.

May 17, 2019
·
2 min read
·
Mark Terry
Business

QIAGEN and Inovio Team Up to Create Companion Diagnostic for HPV Cervical Dysplasia

The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.

May 17, 2019
·
3 min read
·
Mark Terry
Lone Star Bio

Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial

The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.

May 17, 2019
·
2 min read
·
Alex Keown
Policy

FDA’s Project Facilitate to Launch by End of May

Project Facilitate is a pilot project to create a single point of contact for the FDA’s oncology expanded access requests.

May 17, 2019
·
3 min read
·
Mark Terry
Drug Development

AbbVie Halts Brain Tumor Study Due to Lack of Survival Benefits

An Independent Data Monitoring Committee recommended the trial be stopped because of lack of survival benefit for patients receiving the drug compared to placebo.

May 17, 2019
·
2 min read
·
Mark Terry